Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

A TikTok Trend Sold Out Ozempic, Leaving People With Diabetes Dizzy, Scared

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration.
For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn't been able to get his diabetes medication.

Ozempic, an injection that keeps blood sugar levels in check for patients with type 2 diabetes, has been in shortage for about four months, according to the database maintained by the US Food and Drug Administration, and is backordered at Anthony's Seattle pharmacy. 

Without the Novo Nordisk A/S-made prescription, he has suffered recurring dizzy spells while repairing cars. Alternative medications are either out of stock or not covered by his insurance.

While increased demand and supply chain delays have left multiple medicines from the antibiotic amoxicillin to Adderall in short supply, the reason for a lack of certain diabetes drugs is unusual: doctors are prescribing them to non-diabetics who want to use them for weight loss.

"All these famous people, stars who don't need to lose weight, are going and getting it," Mr Anthony said. "I need it to stay healthy and not die."

For the more than 35 million people who live with type 2 diabetes, the shortages have added yet another layer to managing an already complicated and costly chronic illness. They've also exposed weaknesses in America's use of off-label prescribing, which allows physicians to hand out drugs to treat a different condition than the one for which they were officially approved. When those medications are hard to find because of celebrity and social-media hype, patients with diabetes suffer.

Ozempic, known generically as semaglutide, is one of a class of diabetes drugs known as GLP-1 receptor agonists that have been around for nearly two decades. It was first approved in the US in 2017 for use in those with type 2 diabetes. Ozempic mimics a hormone involved in appetite and eating, helping to stimulate insulin production and lower patients' blood glucose levels. It also often leads to them shedding pounds.

Francisco Prieto, a family physician in Sacramento, California, sees at least one person with diabetes per week who is having trouble filling their prescription for Ozempic. Patients will call multiple pharmacies and drive around town to see if it's in stock, but some still haven't been able to get it, said Mr Prieto, who also does advocacy work for the American Diabetes Association.

Recently, one of Mr Prieto's patients experienced a three week-long delay filling a prescription for Trulicity, a similar type 2 diabetes drug that's also seeing increased demand for weight-loss use. Mr Prieto prescribed a lower dose, and recommended that the patient take two injections a week. He described the compromise as "less than ideal, but better than nothing."

Without their medication, patients with diabetes could be at higher risk for things like heart disease, heart attacks, infections like Covid, disability and even death, Mr Prieto said. And while getting a different prescription can be an option, it can come with new hurdles, including insurance coverage and closer monitoring in case the alternative doesn't work as well.

Both new and established users of Ozempic are being affected by periodic supply disruptions. A representative for manufacturer Novo Nordisk said in a statement that the issues are expected to continue through January. The company cited "incredible demand" and short-term capacity limitations at some factories, and said that it is investing to grow manufacturing.

Higher doses of Ozempic that aren't usually given to new patients are available, and Novo's other GLP-1 drugs for diabetes aren't in short supply, though there may be normal delays at pharmacies, the company said. In an earnings presentation in November, Novo said that its sales, as measured in Danish kroner, grew by 26% in the first nine months of the year, largely because of higher demand for Ozempic and other diabetes drugs.

Eli Lilly & Co.'s Trulicity and Mounjaro, both approved to treat type 2 diabetes, are also seeing demand that's resulting in backorders on some doses at pharmacies, a Lilly spokeswoman said. The drugs were listed as being in shortage by the FDA on Thursday. Lilly isn't having supply chain or manufacturing issues, though the company is working to double manufacturing capacity for the category by the end of next year, the spokeswoman said.

Though off-label prescribing is common and legal in the US, it has long created issues. In the early months of the Covid-19 pandemic, for example, people took an unproven drug called hydroxychloroquine, which they believed helped with the virus. That created shortages for patients who take it for lupus and arthritis.

Ozempic is a good candidate for off-label use for obesity, which is also considered a disease and can put people at higher risk for other conditions: official ads for the drug say patients lose on average up to 12 pounds when taking it. It's just not clear that everyone using the drug has a medical need for it.

On TikTok, some videos featuring the hashtag Ozempic have been viewed more than a million times. Medical spas offer the prescription alongside shots of Botox and laser hair removal. Sponsored ads on Google promise weight loss with no exercise or dieting. A plastic surgeon brags on Facebook about using the drug to lose 10 pounds she gained during Covid, and says to call her office to get started.

The FDA doesn't regulate this kind of prescribing. That means many decisions about what to do are up to individuals.

"Which disease is most acute and most severe? Which has alternatives? How adequate are those alternatives?" said Holly Fernandez Lynch, an assistant professor of medical ethics and law at the University of Pennsylvania. "These are the kinds of questions that would help you figure out which patients should have priority access."

Fernandez Lynch said a judgement would depend on the individual case. But those who just want to lose a few pounds shouldn't take a scarce resource that someone else needs, she said.

In Seattle, Mr Anthony has recently been able to get an alternative diabetes drug. It's a much older treatment that requires twice-a-day injections before mealtimes, which he didn't have to think about with Ozempic and has found challenging. It's too soon to know how well it will work for him.

Mr Prieto, the family physician, said his patients are scared and alarmed about the shortage - especially if the drug has really helped improve their health.

"Right now, diabetes is the greater danger, and those folks have a higher need for the drug," he said.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Vatican hosts first Catholic LGBTQ pilgrimage
Apple Unveils iPhone 17 Series, iPhone Air, Apple Watch 11 and More at 'Awe Dropping' Event
France joins Eurozone’s ‘periphery’ as turmoil deepens, say investors
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
France, at an Impasse, Heads Toward Another Government Collapse
The Country That Got Too Rich? Public Spending Dominates Norway Election
EU Proposes Phasing Out Russian Oil and Gas by End of 2027 to End Energy Dependence
More Than 150,000 Followers for a Fictional Character: The New Influencers Are AI Creations
EU Prepares for War
Trump Threatens Retaliatory Tariffs After EU Imposes €2.95 Billion Fine on Google
Tesla Board Proposes Unprecedented One-Trillion-Dollar Performance Package for Elon Musk
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Big Tech Executives Laud Trump at White House Dinner, Unveil Massive U.S. Investments
Tether Expands into Gold Sector with Profit-Driven Diversification
‘Looks Like a Wig’: Online Users Express Concern Over Kate Middleton
Florida’s Vaccine Revolution: DeSantis Declares War on Mandates
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
"The Situation Has Never Been This Bad": The Fall of PepsiCo
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
The Fashion Designer Who Became an Italian Symbol: Giorgio Armani Has Died at 91
Putin Celebrates ‘Unprecedentedly High’ Ties with China as Gazprom Seals Power of Siberia-2 Deal
China Unveils New Weapons in Grand Military Parade as Xi Hosts Putin and Kim
Rapper Cardi B Cleared of Liability in Los Angeles Civil Assault Trial
Google Avoids Break-Up in U.S. Antitrust Case as Stocks Rise
Couple celebrates 80th wedding anniversary at assisted living facility in Lancaster
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
The White House on LinkedIn Has Changed Their Profile Picture to Donald Trump
"Insulted the Prophet Muhammad": Woman Burned Alive by Angry Mob in Niger State, Nigeria
Trump Responds to Death Rumors – Announces 'Missile City'
Druzhba Pipeline Incident Sparks Geopolitical Tensions
Cost of Opposition Leader Péter Magyar's Economic Plan Revealed
Germany in Turmoil: Ukrainian Teenage Girl Pushed to Death by Illegal Iraqi Migrant
United Krack down on human rights: Graham Linehan Arrested at Heathrow Over Three X Posts, Hospitalised, Released on Bail with Posting Ban
Asian and Middle Eastern Investors Avoid US Markets
Ray Dalio Warns of US Shift to Autocracy
Eurozone Inflation Rises to 2.1% in August
Russia and China Sign New Gas Pipeline Deal
Von der Leyen's Plane Hit by Suspected Russian GPS Interference in an Incident Believed to Be Caused by Russia or by Pro-Peace or by Anti-Corruption European Activists
China's Robotics Industry Fuels Export Surge
Suntory Chairman Resigns After Police Probe
Gold Price Hits New All-Time Record
UK Fintechs Explore Buying US Banks
Greece Suspends 5% of Schools as Birth Rate Drops
Apollo to Launch $5 Billion Sports Investment Vehicle
Bolsonaro Trial Nears Close Amid US-Brazil Tension
European Banks Push for Lower Cross-Border Barriers
Poland's Offshore Wind Sector Attracts Investors
×